RATIONALE FOR A BATTERY OF EXPERIMENTAL MODELS FOR THE PRECLINICAL ASSESSMENT OF THE ANTIPARKINSONIAN ACTIVITY OF HYBRID HETEROCYCLIC COMPOUNDS
Annotatsiya
Current therapy for Parkinson's disease is predominantly symptomatic and does not prevent the loss of dopaminergic neurons in the substantia nigra. This sustains interest in new structural classes of compounds, among which hybrid heterocycles combining isoquinoline and quinoline fragments within a single molecule appear promising. Such compounds do not occur in nature, and their antiparkinsonian activity, range of effective doses and mechanism of action have not been studied systematically. At the same time, the validity of any future conclusion about the activity of such compounds depends directly on how appropriately the set of experimental models is chosen, since different models of parkinsonian syndrome reproduce different links in its pathogenesis and are not interchangeable.
Hali tarjima qilinmagan